# Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

> **NCT02991456** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 48 (actual)

## Conditions studied

- Chemo-radiation Induced Nausea and Vomiting

## Interventions

- **DRUG:** Rolapitant
- **DRUG:** Ondansetron

## Key facts

- **NCT ID:** NCT02991456
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2022-05-09
- **Final completion:** 2022-06-20
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991456, "Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02991456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*